Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?

Fragoulis GE, Chatzidionysiou K.

Clin Rheumatol. 2019 Dec 13. doi: 10.1007/s10067-019-04882-x. [Epub ahead of print] Review.

PMID:
31836935
2.

Validation of new classification criteria of rheumatoid arthritis in an international multicentre study.

Li R, Sun X, Ye H, Liu J, Zhao J, Liu X, Mei Y, Zhang Z, Guo J, Bi L, Liu X, Wang G, Liu J, Leng X, Gu F, Sun L, Zou Q, Fang Y, Jiang Q, Chatzidionysiou K, Priya S, Janardana R, Nair A, Catrina AI, Danda D, Li ZG.

Clin Exp Rheumatol. 2019 Dec 9. [Epub ahead of print]

PMID:
31820726
3.

Effect of belimumab treatment on antiphospholipid antibodies levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus.

Chatzidionysiou K, Samoli E, Sfikakis PP, Tektonidou MG.

Ann Rheum Dis. 2019 Nov 11. pii: annrheumdis-2019-216367. doi: 10.1136/annrheumdis-2019-216367. [Epub ahead of print] No abstract available.

PMID:
31712248
4.

Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift.

Chatzidionysiou K, Sfikakis PP.

RMD Open. 2019 Jul 27;5(2):e000993. doi: 10.1136/rmdopen-2019-000993. eCollection 2019. Review.

5.

Protective Effect of the HIF-1A Pro582Ser Polymorphism on Severe Diabetic Retinopathy.

Ekberg NR, Eliasson S, Li YW, Zheng X, Chatzidionysiou K, Falhammar H, Gu HF, Catrina SB.

J Diabetes Res. 2019 May 12;2019:2936962. doi: 10.1155/2019/2936962. eCollection 2019.

6.

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.

Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K.

Rheumatology (Oxford). 2019 Dec 1;58(12):2170-2176. doi: 10.1093/rheumatology/kez191.

7.

Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.

Parodis I, Gomez A, Emamikia S, Chatzidionysiou K.

Ann Rheum Dis. 2019 Jul;78(7):1006-1007. doi: 10.1136/annrheumdis-2018-214880. Epub 2019 Jan 4. No abstract available.

PMID:
30610063
8.

Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies.

Parodis I, Emamikia S, Gomez A, Gunnarsson I, van Vollenhoven RF, Chatzidionysiou K.

Expert Opin Biol Ther. 2019 Feb;19(2):157-168. doi: 10.1080/14712598.2019.1561856. Epub 2018 Dec 27.

PMID:
30571926
9.

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort.

Giannakou I, Chatzidionysiou K, Magder LS, Györi N, van Vollenhoven R, Petri MA.

Lupus Sci Med. 2018 Nov 2;5(1):e000287. doi: 10.1136/lupus-2018-000287. eCollection 2018.

10.

Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.

Chatzidionysiou K, Lukina G, Gabay C, Hetland ML, Hauge EM, Pavelka K, Nordström D, Canhão H, Tomsic M, Rotar Z, Lie E, Kvien TK, van Vollenhoven RF, Saevarsdottir S.

Scand J Rheumatol. 2019 Jan;48(1):17-23. doi: 10.1080/03009742.2018.1466363. Epub 2018 Sep 27.

PMID:
30260261
11.

Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries.

Glintborg B, Lindström U, Aaltonen K, Kristianslund EK, Gudbjornsson B, Chatzidionysiou K, Askling J, Nordström D, Hetland ML, Di Giuseppe D, Dreyer L, Kristensen LE, Jørgensen TS, Eklund K, Grondal G, Ernestam S, Joensuu J, Törmänen M, Skydsgaard H, Hagfors J, Kvien TK, Lie E, Fagerli K, Geirsson AJ, Jonsson H, Provan SA, Krogh NS, Jacobsson L.

Scand J Rheumatol. 2018 Nov;47(6):465-474. doi: 10.1080/03009742.2018.1444199. Epub 2018 Aug 2.

PMID:
30070923
12.

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.

Chatzidionysiou K, Hetland ML, Frisell T, Di Giuseppe D, Hellgren K, Glintborg B, Nordström D, Aaltonen K, Törmänen MR, Klami Kristianslund E, Kvien TK, Provan SA, Björn Guðbjörnsson B, Dreyer L, Kristensen LE, Jørgensen TS, Jacobsson L, Askling J.

RMD Open. 2018 Apr 12;4(1):e000655. doi: 10.1136/rmdopen-2018-000655. eCollection 2018. Review. Erratum in: RMD Open. 2018 May 14;4(1):.

13.

2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis.

Radner H, Chatzidionysiou K, Nikiphorou E, Gossec L, Hyrich KL, Zabalan C, van Eijk-Hustings Y, Williamson PR, Balanescu A, Burmester GR, Carmona L, Dougados M, Finckh A, Haugeberg G, Hetland ML, Oliver S, Porter D, Raza K, Ryan P, Santos MJ, van der Helm-van Mil A, van Riel P, von Krause G, Zavada J, Dixon WG, Askling J.

Ann Rheum Dis. 2018 Apr;77(4):476-479. doi: 10.1136/annrheumdis-2017-212256. Epub 2018 Jan 4.

PMID:
29301783
14.

Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial.

Emamikia S, Gentline C, Chatzidionysiou K, Arnaud L, van Vollenhoven R.

Scand J Rheumatol. 2018 Mar;47(2):131-140. doi: 10.1080/03009742.2017.1336570. Epub 2017 Sep 1.

PMID:
28862513
15.

Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.

Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, van der Heijde D, Dougados M, Bijlsma J, Burmester G, Scholte M, van Vollenhoven R, Landewé R.

Ann Rheum Dis. 2017 Jun;76(6):1102-1107. doi: 10.1136/annrheumdis-2016-210711. Epub 2017 Mar 29. Review.

PMID:
28356243
16.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, Scholte-Voshaar M, Falzon L, Landewé RBM.

Ann Rheum Dis. 2017 Jun;76(6):1101-1136. doi: 10.1136/annrheumdis-2016-210708. Epub 2017 Mar 15. Review.

PMID:
28298374
17.

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.

Nam JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, Smolen JS, van der Heijde D, Bijlsma JW, Burmester GR, Dougados M, Scholte-Voshaar M, van Vollenhoven R, Landewé R.

Ann Rheum Dis. 2017 Jun;76(6):1113-1136. doi: 10.1136/annrheumdis-2016-210713. Epub 2017 Mar 10. Review.

PMID:
28283512
18.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

19.

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort.

Györi N, Giannakou I, Chatzidionysiou K, Magder L, van Vollenhoven RF, Petri M.

Lupus Sci Med. 2017 Feb 8;4(1):e000192. doi: 10.1136/lupus-2016-000192. eCollection 2017.

20.

Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.

Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Hauge EM, Pavelka K, Gabay C, Scherer A, Nordström D, Canhao H, Santos MJ, Tomsic M, Rotar Z, Hernández MV, Gomez-Reino J, Ancuta I, Kvien TK, van Vollenhoven R.

J Rheumatol. 2017 Feb;44(2):162-169. doi: 10.3899/jrheum.160460. Epub 2017 Jan 15.

PMID:
28089978
21.

Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature.

Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalan C, van Eijk-Hustings Y, Dixon WG, Hyrich KL, Askling J, Gossec L.

Arthritis Res Ther. 2016 Oct 28;18(1):251. Review.

22.

Optimizing biological treatments for rheumatoid arthritis.

Chatzidionysiou K.

Scand J Rheumatol. 2016 Aug;45(sup128):64-75.

PMID:
27687484
23.

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials.

Emamikia S, Arkema EV, Györi N, Detert J, Chatzidionysiou K, Dougados M, Burmester GR, van Vollenhoven R.

RMD Open. 2016 Sep 6;2(2):e000323. doi: 10.1136/rmdopen-2016-000323. eCollection 2016.

24.

Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF.

Arthritis Res Ther. 2016 Jun 20;18(1):144. No abstract available.

25.

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF; Rheumatic Diseases Portuguese Register.

Arthritis Res Ther. 2016 Feb 16;18:50. doi: 10.1186/s13075-016-0951-z. Erratum in: Arthritis Res Ther. 2016;18(1):144.

26.

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, Cöster L, Forslind K, van Vollenhoven R, Heimbürger M.

RMD Open. 2016 Jan 14;2(1):e000133. doi: 10.1136/rmdopen-2015-000133. eCollection 2016.

27.

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.

Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomšič M, Canhao H, Chatzidionysiou K, Lukina G, Nordström DC, Lie E, Ancuta I, Hernández MV, van Riel PL, van Vollenhoven R, Kvien TK.

Ann Rheum Dis. 2016 Jul;75(7):1336-42. doi: 10.1136/annrheumdis-2015-207760. Epub 2015 Sep 15.

28.

Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.

Walker UA, Jaeger VK, Chatzidionysiou K, Hetland ML, Hauge EM, Pavelka K, Nordström DC, Canhão H, Tomšič M, van Vollenhoven R, Gabay C.

Rheumatology (Oxford). 2016 Feb;55(2):230-6. doi: 10.1093/rheumatology/kev297. Epub 2015 Aug 27.

PMID:
26316581
29.

Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.

Chatzidionysiou K, Kristensen LE, Eriksson J, Askling J, van Vollenhoven R; ARTIS Group.

Scand J Rheumatol. 2015;44(6):431-7. doi: 10.3109/03009742.2015.1026840. Epub 2015 Jun 18.

PMID:
26084325
30.

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.

Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R; ARTIS group.

Ann Rheum Dis. 2015 May;74(5):890-6. doi: 10.1136/annrheumdis-2013-204714. Epub 2014 Jan 15.

PMID:
24431398
31.

Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?

van Vollenhoven RF, Chatzidionysiou K.

Nat Rev Rheumatol. 2013 Sep;9(9):510-2. doi: 10.1038/nrrheum.2013.118. Epub 2013 Jul 30.

PMID:
23897440
32.

Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort.

Chatzidionysiou K, van Vollenhoven RF.

Scand J Rheumatol. 2013;42(3):190-5. doi: 10.3109/03009742.2012.729607. Epub 2013 Jan 3.

PMID:
23286833
33.

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, Chatzidionysiou K, Bratt J; Swefot study group.

Lancet. 2012 May 5;379(9827):1712-20. doi: 10.1016/S0140-6736(12)60027-0. Epub 2012 Mar 29.

PMID:
22464340
34.

Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF, Gabay C.

Ann Rheum Dis. 2012 Mar;71(3):374-7. doi: 10.1136/annrheumdis-2011-200003. Epub 2011 Oct 4.

PMID:
21972242
35.

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF.

Ann Rheum Dis. 2011 Sep;70(9):1575-80. doi: 10.1136/ard.2010.148759. Epub 2011 May 12.

PMID:
21571731
36.

When to initiate and discontinue biologic treatments for rheumatoid arthritis?

Chatzidionysiou K, van Vollenhoven RF.

J Intern Med. 2011 Jun;269(6):614-25. doi: 10.1111/j.1365-2796.2011.02355.x. Epub 2011 Feb 23. Review.

Supplemental Content

Loading ...
Support Center